Newbury Pharmaceuticals AB (NEWBRY) — Financial Flexibility Index
Newbury Pharmaceuticals AB (NEWBRY) has a Financial Flexibility Index of 0.05x as of February 2026. Free cash flow of Skr2.26 Million (operating CF Skr2.26 Million minus capex Skr0.00) represents 0% of total liabilities (Skr45.96 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Newbury Pharmaceuticals AB Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for Newbury Pharmaceuticals AB across 4 annual periods. See working capital to net assets of Newbury Pharmaceuticals AB to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Newbury Pharmaceuticals AB (2021–2024)
Year-by-year free cash flow to debt coverage for Newbury Pharmaceuticals AB. For the full company profile including market capitalisation, see NEWBRY stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | Skr-20.80 Million | Skr-23.71 Million | Skr38.95 Million | ▲ +43.8% |
| 2023 | -0.95x | Skr-22.36 Million | Skr-23.23 Million | Skr23.54 Million | ▼ -283.4% |
| 2022 | 0.52x | Skr9.40 Million | Skr-15.00 Million | Skr18.14 Million | ▼ -88.2% |
| 2021 | 4.38x | Skr19.02 Million | Skr-4.07 Million | Skr4.34 Million | — |